Pune: Serum Institute of India’s (SII) phase 2 trial of Oxford’s COVID-19 vaccine candidate is set to commence on Tuesday.
The determination of safety and immunogenicity of “Covishield” on healthy Indian adults will start at Bharati Vidyapeeth Medical College and Hospital here.
SII has collaborated with AstraZeneca, a British-Swedish pharma company, for manufacturing of the University of Oxford-developed COVID-19 vaccine candidate.
“We have got all approvals from the Central Drugs Standard Control Organisation (CDSCO). We are going to start the human clinical trial process at the Bharati Vidyapeeth (Deemed to be University) Medical College and Hospital from August 25.
“We are sure that in line with the philosophy of our group, we are going to make available a world class Covid-19 vaccine for people of our country and make our country ‘AatmaNirbhar’,” SSI’s additional director, Government and Regulatory Affairs, Prakash Kumar Singh was quoted as saying by news agency PTI.
Bargarh: A new artist will be selected to play the mythological character King Kansa during…
Mumbai: Suhana Khan will be making her Bollywood debut with ‘King’ along with her superstar…
New Delhi: After Diljit Dosanjh called out the double standards of Telangana government for banning…
New Delhi: Recent actions and counter-actions in the Russia-Ukraine conflict have pushed the world to the…
Balangir: Three persons were arrested and fake IPS officers’ uniforms along with fake identity cards…
Mumbai: Abhishek Bachchan’s highly-anticipated film ‘I Want To Talk’ released in theatres on Friday, and the…
New Delhi: Accused of giving cash to secure votes ahead of election day in Maharashtra,…
Bhubaneswar: Chief Minister Mohan Charan Majhi attended the ‘Odisha State Day Celebrations’ at the 43rd…